This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

(1) Neuhaus O et al (2001). Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology, 56, 702-8.

(2) Copaxone. Summary of Product Characteristics, UK. Teva Pharmaceuticals Ltd, April 2001.

(3) Johnson KP et al (2000). Sustained clinical benefits of glatiramer acetate in relaping multiple sclerosis patients observed for 6 years. Mult Scler, 6, 255-66.

(4) Bornstein MB et al (1987). A pilot trial of Cop1 in exacerbating-remitting multiple sclerosis. NEJM, 317, 408-14.

(5) Drugs and Therapeutics Bulletin (2001), 39 (6), 41-2.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.